Zhijian Huang | Oncology | Excellence in Research

Dr. Zhijian Huang | Oncology | Excellence in Research

Fujian Cancer Hospital | China

Dr. Zhijian Huang is a distinguished Deputy Chief Physician at the Department of Breast Surgical Oncology at Fujian Medical University Cancer Hospital in Fuzhou, China. With extensive expertise in breast cancer treatment and reconstructive surgery, Dr. Huang has contributed significantly to understanding tumor metastasis mechanisms and immunological factors in breast cancer. He is currently expanding his research at Harvard University Beth Israel Deaconess Medical Center, focusing on molecular pathways and predictive models.

Professional profile👤

Google Scholar

Strengths for the Awards✨

  • Extensive Research Contributions: Dr. Huang has an impressive publication record, with 14 peer-reviewed articles, many in high-impact journals such as Frontiers in Oncology, BMC Cancer, and Biosafety and Health. His research spans crucial areas of breast cancer, including tumor metastasis mechanisms, immune microenvironments, and biomarker discovery.
  • Interdisciplinary Expertise: His skills in bioinformatics, molecular biology techniques (e.g., CRISPR/Cas9 gene editing), and clinical integration set him apart as a versatile researcher capable of bridging computational and experimental oncology.
  • Clinical Impact: Dr. Huang has contributed directly to patient care through advancements in comprehensive breast cancer treatment, breast reconstruction techniques, and real-world studies of therapeutic efficacy.
  • Recognition and Leadership: The two prestigious awards he received in 2023 for his work on artificial intelligence in breast cancer diagnostics and immune microenvironments reflect the impact and recognition of his research in the medical community.
  • International Collaboration: His postdoctoral research at Harvard University’s Beth Israel Deaconess Medical Center adds a global dimension to his work and highlights his active engagement in cutting-edge breast cancer research.

Education 🎓

Dr. Huang earned his Doctor of Medicine (M.D.) in Clinical Medicine from Southern Medical University in Guangzhou, China, in 2022. Prior to that, he completed his Master of Medicine at Fujian Medical University in 2009 and his Bachelor of Medicine at the same institution in 2005.

Experience 💼

Dr. Huang has been serving at Fujian Medical University Cancer Hospital since 2009, performing breast tumor surgeries, comprehensive treatments, and breast reconstructions. From 2016 to 2017, he trained at the Affiliated Cancer Hospital of Xiangya Medical College, focusing on advanced tumor plastic surgery techniques. In 2024, he joined Harvard University Beth Israel Deaconess Medical Center as a Postdoctoral Researcher, delving deeper into breast cancer mechanisms and therapeutic advancements.

Research Interests On Oncology🔬

His research revolves around tumor metastasis mechanisms, breast cancer immunology, and molecular biology techniques. He is skilled in Western blotting, lentiviral packaging, CRISPR/Cas9 gene editing, and developing mouse models. Dr. Huang also specializes in bioinformatics analysis, employing tools like SPSS and GraphPad Prism.

Awards 🏆

  • 2023: Third Prize, Fujian Medical Science and Technology Award for research on ultrasound-assisted artificial intelligence diagnosis of breast cancer, immune microenvironment, and metastatic molecular mechanisms.
  • 2023: Third Prize, Fujian Anti-Cancer Association Science and Technology Award for research on immune microenvironment, metastatic molecular mechanisms of breast cancer, and infusion port clinical applications.

Publications 📚

  • Title: Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer
    Authors: C Xiao, L Yang, L Jin, W Lin, F Zhang, S Huang, Z Huang
    Year: 2022
    Citations: 42

  • Title: Application of oncolytic virus in tumor therapy
    Authors: Z Huang, H Guo, L Lin, S Li, Y Yang, Y Han, W Huang, J Yang
    Year: 2023
    Citations: 29

  • Title: A novel XGBoost method to infer the primary lesion of 20 solid tumor types from gene expression data
    Authors: S Chen, W Zhou, J Tu, J Li, B Wang, X Mo, G Tian, K Lv, Z Huang
    Year: 2021
    Citations: 14

  • Title: miRNA-1260b promotes breast cancer cell migration and invasion by downregulating CCDC134
    Authors: Z Huang, S Zhen, L Jin, J Chen, Y Han, W Lei, F Zhang
    Year: 2023
    Citations: 12

  • Title: A novel framework to predict breast cancer prognosis using immune-associated LncRNAs
    Authors: Z Huang, C Xiao, F Zhang, Z Zhou, L Yu, C Ye, W Huang, N Li
    Year: 2021
    Citations: 12

  • Title: HAUS5 is a potential prognostic biomarker with functional significance in breast cancer
    Authors: Z Huang, J Yang, W Qiu, J Huang, Z Chen, Y Han, C Ye
    Year: 2022
    Citations: 10

  • Title: 肝癌病人术后早期肠内与肠外营养支持治疗的比较
    Authors: 周东, 刘胜, 应敏刚, 黄峰, 吴贤毅, 黄志坚
    Year: 2012
    Citations: 10

  • Title: Comprehensive analysis of immune ferroptosis gene in renal clear cell carcinoma: Prognosis and influence of tumor microenvironment
    Authors: LH Yang, LZ Xu, ZJ Huang, HH Pan, M Wu, QY Wu, T Lu, YP Zhang
    Year: 2022
    Citations: 5

  • Title: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer
    Authors: W Huang, C Wang, Y Shen, Q Chen, Z Huang, J Liu, X Lin, L Wang, F Wu
    Year: 2024
    Citations: 4

  • Title: Systematic pan-cancer analysis identifies cGAS as an immunological and prognostic biomarker
    Authors: P Chen, X Yang, P Wang, H He, Y Chen, L Yu, H Fang, F Wang, Z Huang
    Year: 2023
    Citations: 4

Conclusion 🔖

Dr. Zhijian Huang’s illustrious career is marked by a deep commitment to advancing breast cancer treatment through surgical expertise and cutting-edge research. His work continues to shape the future of cancer therapy, bridging molecular insights with clinical applications to improve patient outcomes worldwide.

Juan Ren | Oncology | Excellence in Research

Prof. Dr. Juan Ren | Oncology | Excellence in Research

Professor | The First Affiliated Hospital of Xi’an Jiaotong University | China

Dr. Juan Ren, M.D., Ph.D., is a distinguished professor at the Cancer Center of the First Affiliated Hospital of Xi’an Jiaotong University. With a profound dedication to oncology research, she has made significant contributions to understanding cancer biology, particularly in ovarian and endometrial cancers. Her research has led to advancements in tumor markers, angiogenesis, and targeted therapies, establishing her as a leading figure in the field of cancer research.

Profile👤

Scopus

Strengths for the Awards✨

Extensive Research Experience: Dr. Juan Ren has led multiple research projects as a Principal Investigator under prestigious grants, including the National Natural Science Foundation of China and Science & Technology Grants of Shaan’ Xi Province. These projects focus on ovarian cancer, angiogenesis, and targeted cancer therapies, demonstrating a strong track record in cutting-edge oncology research.

Outstanding Publication Record: With over 30 peer-reviewed publications in high-impact journals like Cancer Research, FASEB Journal, and the Journal of Biological Chemistry, Dr. Ren has significantly contributed to the field of cancer biology, epigenetics, and targeted therapy. Publications address crucial aspects of cancer metastasis, angiogenesis, and drug resistance, which align with innovative approaches in cancer treatment.

Recognized Achievements and Awards: Dr. Ren has received multiple prestigious awards, including the First and Second Awards for Excellence in Science and Technology from the Shaan’ Xi Provincial Government and the Cleveland Clinic Foundation’s Excellent Research Award. These accolades highlight a well-respected and impactful career in scientific research.

International Collaboration & Impact: Having worked with institutions like the Cleveland Clinic Foundation, USA, Dr. Ren has demonstrated global research engagement, making their work influential beyond China.

Innovative Contributions to Cancer Treatment: Research focusing on GPR4, VEGF receptors, phospholipase A2 inhibitors, and epigenetic interventions positions Dr. Ren as a pioneer in targeted therapies and precision medicine for cancer treatment.

Education 🎓

Dr. Ren earned her medical degree from Xi’an Medical University, where she was recognized as an outstanding student. She later pursued a Ph.D. at Xi’an Jiaotong University, focusing on cancer research. Her academic excellence was further acknowledged with prestigious awards, highlighting her dedication and contributions to medical science.

Experience 🏥

Dr. Ren has held key positions in academia and research. As a principal investigator, she has led multiple groundbreaking projects funded by the National Natural Science Foundation of China. Her research has explored the molecular mechanisms of cancer progression, metastasis, and treatment resistance. She has collaborated with international institutions, further enriching her expertise and contributions to oncology.

Research Interests On Oncology 🔬

Dr. Ren’s research focuses on:

  • The molecular mechanisms of ovarian and endometrial cancers.
  • Tumor markers for early cancer detection.
  • The role of G-protein-coupled receptors in angiogenesis.
  • Epigenetic interventions to enhance cancer treatment.
  • The development of novel targeted therapies for gynecological malignancies.

Awards 🏆

Dr. Ren has received numerous prestigious awards, including:

  • Second Award of Achievement & Excellence in Science and Technology, Shaan’Xi Province (2013).
  • First Award of Achievement & Excellence in Science and Technology, Shaan’Xi Province (2009).
  • First Award of Achievement & Excellence in Science and Technology, Anti-Cancer Association of Shaan’Xi Province (2006).
  • Excellent Research Award, Cleveland Clinic Foundation, USA (2004).
  • Multiple awards for scientific excellence from Xi’an Jiaotong University and the Education Bureau.

Publications 📄

Dr. Ren has authored numerous high-impact research articles. Some key publications include:

  • Title: MECOM Locus Classical Transcript Isoforms Affect Tumor Immune Microenvironment and Different Targets in Ovarian Cancer
    Authors: N. Lan, S. Bai, M. Chen, F. Wu, J. Ren
    Publication Year: 2024

  • Title: Predictive Role of Elevated Neutrophil-Lymphocyte Ratio for Bone Metastasis in Esophageal Cancer
    Authors: X. Wang, Y. Gao, J. Wang, F. Wu, J. Ren
    Publication Year: 2024

  • Title: Construction of lncRNA-m6A Gene-mRNA Regulatory Network to Identify m6A-Related lncRNAs Associated with the Progression of Lung Adenocarcinoma
    Authors: J. Zhang, S. Bai, Y. Yan, X. Wang, J. Ren
    Publication Year: 2023

  • Title: Perspective of Radiotherapy for Ovarian Metastasis from Small Cell Lung Cancer
    Authors: Z. Feng, Y. Qu, X. Sun, X. Zhang, Y. Yang
    Publication Year: 2023

  • Title: Construction of Prognostic Model of Ovarian Cancer Patients Based on Immune-Related Genes
    Authors: H. Kang, S. Bai, R. Li, J. Zhang, J. Ren
    Publication Year: 2023

  • Title: Clinical Association Between Coagulation Indicators and Bone Metastasis in Patients with Gastric Cancer
    Authors: X. Wang, M. Chen, J. Ren, X. Zhang
    Publication Year: 2023

Conclusion 🔍

Dr. Juan Ren’s dedication to oncology research has significantly advanced the understanding of cancer biology. Her contributions in tumor marker identification, molecular targeting, and cancer therapy have shaped modern oncology. Through her research, leadership, and clinical expertise, she continues to inspire and drive innovation in cancer treatment, making a lasting impact on the medical community worldwide.